Working… Menu

The Kinetics of Endocannabinoids in Patients With Chemotherapy Induced Peripheral Neuropathy by Using Medical Cannabis.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04376437
Recruitment Status : Not yet recruiting
First Posted : May 6, 2020
Last Update Posted : July 29, 2020
Technion, Israel Institute of Technology
Syqe Medical
Information provided by (Responsible Party):
Gil Bar Sela, HaEmek Medical Center, Israel

Brief Summary:

Chemotherapy-induced peripheral neuropathy (CIPN) is the most common neurological cancer treatment complication. Medical cannabis is indicated in Israel for the treatment of chronic pain, spasticity and for the control of pain and other symptoms in patients with cancer.

The proposed study aims are to study about the changes in level of endocannabinoids following continuous exposure to phytocannabinoids and about the long-term effect of medical cannabis on CIPN.

Condition or disease Intervention/treatment Phase
Chemotherapy-induced Peripheral Neuropathy Drug: medical cannabis Not Applicable

Detailed Description:

This will be a self-titrated, open-label design study. Subjects who begin taxanes or oxaliplatine therapy and were diagnosed with CIPN will be recruited to the study.

After providing their written informed consent, the study physician obtained a medical history, demographic details and conducted a physical examination. During the current study, baseline period for CIPN evaluation will be 2 weeks, while patients will fill several questionnaires. Baseline CIPN will be evaluating by DN4 and BPI questionnaires. EQ-5D and PSQI will be filled for baseline Quality of life (QOL) and sleepiness status, accordingly.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Syqe Medical Cannabis inhaler is approval medical device in Israel , this is only Basic science study with main purpose to learn more about the kinetics of endocannabinoids .
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Kinetics of Endocannabinoids in Patients With Chemotherapy Induced Peripheral Neuropathy by Using a Portable Metered-Dose Cannabis Inhaler
Estimated Study Start Date : September 1, 2020
Estimated Primary Completion Date : February 1, 2022
Estimated Study Completion Date : February 1, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: medical cannabis
All patients will start with 250mcg cannabis flos BID and will follow the titration plan of dose modification according to CIPN relief and adverse events. Maximum dose of 2,000mcg per day is prescribed at the end of titration period, which is continuous for 15 days (about 2 weeks).On 10 weeks visit all patients will be discontinued from the treatment. In case of worsening of neuropathy at any point during the 4 weeks of FU, patients might be able to restart with inhaled MC treatment for no more than 4 weeks. Total treatment in this study will be for no more than 14 weeks.
Drug: medical cannabis
inhalation by using a Portable Metered-Dose Cannabis Inhaler
Other Name: medical marijuana

Primary Outcome Measures :
  1. Changes in the level of 150 different endocannabinoids. [ Time Frame: Determined on blood samples collected during the 4 months of participation in the study ]
    Circulating endocannabinoids concentrations .

Secondary Outcome Measures :
  1. Changes from the baseline of neuropathic pain during medical cannabis treatment . [ Time Frame: during 4 months of participation in the study ]
    Neuropathic pain detected by DN4 questionnaire .

  2. Changes in Quality of life by FACT-GOG-Ntx [ Time Frame: This exam will be performed every visit.during 4 months of participation in the study ]
    Changes of Quality of life will be evaluated by Functional Assessment of Cancer Therapy - Gynecologic Oncology Group-Neurotoxicity ( FACT-GOG-Ntx) questionnaire

  3. Changes in Quality of life by BPI [ Time Frame: This exam will be performed every visit.during 4 months of participation in the study ]
    Changes of Quality of life will be evaluated by BRIEF PAIN INVENTORY (BPI) tool.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Age above 18 years and below 80 years old. 2. Pathology of Breast or GI malignancies. 3. Treatment with Taxans (Taxol/ Taxotere) or Oxaliplatin for adjuvant treatment or metastatic disease.

    4. Estimated life expectancy ≥ 6 months. 5. Performance status ≤1 (ECOG classification). 6. Sign of written informed consent. 7. CIPN is examined during the chemotherapy treatment DN4 score must be above 4 (and by physician decision) for more than one week.

    8. Patient with adequate liver/renal function at screening as described:

    • Creatinine clearance >30 ml/min as calculated by Cockcroft-Gault Equation.
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN. 9. Patients who suffer from pain although using a stable analgesic treatment' at least 14 days before entering the trial (no limitation for the use of the analgesic).

      10. Patient possessed a valid license from the Israeli Ministry of Health to receive medicinal cannabis.

      11. Patient is able and willing to comply with study requirements. 12. Patient agrees to use only medical cannabis provided by study team until the end of study period.

      13. Patient has not undergone major surgery in the month prior to the study start.

      14. Patient agrees not to participate in other interventional clinical trial during the study participation.

Exclusion Criteria:

  • 1. Use of cannabis or synthetic cannabinoids in the last two weeks (urine test for cannabinoids are positive).

    2. Patient with known or past substance abuse. 3. Patients with major psychiatric disorders (e.g. schizophrenia, dementia, and intellectual disabilities).

    4. Patients with first degree siblings under the age of 30 years old with psychiatric disorders.

    5. Patients with uncontrolled diabetes mellitus, cardiovascular, or convulsive disorders according to investigator.

    6. Patients with sensitivity to cannabis or cannabinoids. 7. Patients with known neuropathic pain due to diabetes or other diseases. 8. Patients with severe respiratory disease. 9. Patients with brain metastases or brain tumors may participate if completed radiotherapy treatment at least 14 days prior to signing the informed consent and last imaging did not show any worsening.

    10. Female subjects who are pregnant, lactating, or want to get pregnant during the study period and one month following the study. Male subjects who want their partner to get pregnant during the study period and one month following the study.

    11. Females of childbearing potential or males whose partners with childbearing potential and did not use adequate contraceptives 28 days prior to study start or during the study.

    12. Other life-threatening medical conditions that disqualify the patient from participating in the study, according to the Primary Investigator's judgment.

    13. Anticipated alcohol or barbiturate use during the study period. 14. Participation in other clinical trials during the last month. 15. Subjects who are using one of the following medications: opiates (Primidone, Phenobarbitol, Arbamazepine, Rifampicin, Rifabutin, Troglitazone and Hypericum perforatum).

    16. Patient who has undergone a major surgery a month prior to study start.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04376437

Layout table for location contacts
Contact: Gil Bar Sela, Prof +97250-206-1207
Contact: Ela Lutwak, M.SC +972546459510

Layout table for location information
Haemek MC
Afula, North, Israel
Sponsors and Collaborators
HaEmek Medical Center, Israel
Technion, Israel Institute of Technology
Syqe Medical
Publications of Results:

Layout table for additonal information
Responsible Party: Gil Bar Sela, Oncologist, HaEmek Medical Center, Israel Identifier: NCT04376437    
Other Study ID Numbers: ENDO-CIPN 1
First Posted: May 6, 2020    Key Record Dates
Last Update Posted: July 29, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases